WINDTREE THERAPEUTICS INC (WINT)

Windtree Announces New Istaroxime Patent Filing for Preventing or Reducing the Risk of Acute Myocardial Arrhythmia

WARRINGTON, Pa., Dec. 09, 2024 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company...

Windtree Announces Partnership with New Growth Advisors to Leverage Positive Phase 2 Istaroxime Study in Cardiogenic Shock for a Potential Strategic Transaction

WARRINGTON, Pa., Dec. 04, 2024 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company...

Windtree Therapeutics Reports Third Quarter 2024 Financial Results and Provides Key Business Updates

WARRINGTON, Pa., Nov. 27, 2024 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or “the Company”) (NasdaqCM: WINT), a biotechnology company...

Sidoti Events, LLC's Virtual November Micro-Cap Conference

Windtree Announces Expansion of Patents with Issuance of Istaroxime Patent for Hong Kong

Supports Licensing Partner’s Phase 3 Activities in Acute Heart Failure...

Windtree Announces Istaroxime Cardiogenic Shock Patent Filings In Countries Around the World

WARRINGTON, Pa., Oct. 23, 2024 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company...

Windtree To Present at the ThinkEquity Conference on October 30th

WARRINGTON, Pa., Oct. 21, 2024 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company...

Windtree Announces Expansion of Patents with Issuance of Istaroxime Patent for Japan

WARRINGTON, Pa., Oct. 17, 2024 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company...

Windtree Announces Publication of Positive Istaroxime Phase 2b Study Trial Design

The Company recently announced the positive topline results from the Phase 2b study with istaroxime in acute heart failure patients with early cardiogenic...

Windtree Announces Positive Phase 2b Topline Clinical Results with Istaroxime Significantly Improving Cardiac Function and Blood Pressure in Heart Failure Patients in Early Cardiogenic Shock

Istaroxime treatment significantly improved systolic blood pressure as well as cardiac output and renal function without increasing heart rate or...

Windtree Therapeutics Announces Virtual Investor Day Presentation on October 1 at 3pm ET

New Istaroxime Phase 2b clinical results to be presented by Windtree and top cardiology expert Review of cardiogenic shock and other programs, including...

Windtree Announces Positive Topline Results from Its Phase 2b SEISMiC Extension Study of Istaroxime in Early Cardiogenic Shock

Istaroxime significantly improved primary endpoint of the systolic blood pressure profile over six hours and showed significant improvements in many...

Windtree Therapeutics Reports Second Quarter 2024 Financial Results and Provides Key Business Updates

WARRINGTON, Pa., Aug. 20, 2024 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company...

WINT Stock Earnings: Windtree Therapeutics Reported Results for Q1 2024

Windtree Therapeutics just reported results for the first quarter of 2024.

WINT Stock Earnings: Windtree Therapeutics Reported Results for Q1 2024

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Windtree Therapeutics (NASDAQ:WINT) just reported results for the first quarter...

Windtree Announces New Additions and Changes to Its Board of Directors

WARRINGTON, Pa., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company...

Why Is DexCom (DXCM) Stock Down 38% Today?

DexCom stock is up on Friday as DXCM investors react to the company's latest earnings report and its lackluster 2024 guidance.

Why Is BurgerFi International (BFI) Stock Up 71% Today?

BurgerFi International stock is up on Friday as investors in BFI react to it reaching a settlement agreement with Lion Point Capital, LP.

Why Is Windtree Therapeutics (WINT) Stock Up 116% Today?

Windtree Therapeutics stock is up on Friday with heavy trading of WINT shares following an update on its clinical trials.